Figure 2. BGE-102 resulted in significant additive weight loss when combined with GLP-1R agonist semaglutide. Group size: n=8–10 per group. BGE-102 50 mpk + semaglutide vs. obese control, Day 27: p<0.0001. Note: BGE-102 is 150–250x more potent in human microglia, the target cell in the brain, compared to mouse microglia, consistent with <50 mg predicted daily dose.
Figure 2. BGE-102 resulted in significant additive weight loss when combined with GLP-1R agonist semaglutide. Group size: n=8–10 per group. BGE-102 50 mpk + semaglutide vs. obese control, Day 27: p<0.0001. Note: BGE-102 is 150–250x more potent in human microglia, the target cell in the brain, compared to mouse microglia, consistent with <50 mg predicted daily dose.